截至2025年7月25日收盘，奥精医疗（688613）报收于19.77元，较上周的18.76元上涨5.38%。本周，奥 精医疗7月22日盘中最高价报20.36元。7月23日盘中最低价报18.59元。奥精医疗当前最新总市值27.09亿 元，在医疗器械板块市值排名115/126，在两市A股市值排名4624/5148。 1. 关于公司产品在越南获得注册证的公告 5. 关于注销募集资金专户的公告 本周关注点 公司公告汇总 奥精医疗科技股份有限公司近期发布了两项重要公告： 公司公告汇总：奥精医疗的人工骨修复材料在越南获得注册证 公司公告汇总：奥精医疗注销兴业银行募集资金专户 2. 奥精医疗的人工骨修复材料于2024年12月向越南卫生部提交注册申请，近日正式获得批准。注册 证编号为2502543ĐKLH/BYT-HTTB，有效期自2025年7月16日起永久有效，产品分类为D类（高 风险医疗器械）。 3. OssaNova人工骨修复材料主要用于口腔科或整形外科无植骨禁忌的骨缺损修复，此前已在中国和 印度尼西亚获得注册证。 4. 此次注册证的获得将有助于公司在海外市场进一步拓展业务，但具体业绩影响尚无法预测。 6. 因募投项 ...

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 即将召开： 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 2025年6月17日， 奥精医疗科技股份有限公司 （证券代码：688613）发布公告称，公司于2024年12月向 越南卫生部递交了人工骨修复材料产品的注册申报资料 ，并于近日收到越南卫生部通知， 该产品获得批准 。 此前，该产品于2014年12月获得 中国国家食品药品监督管理总局 （现国家药品监督管理局）颁发的 第三类 医疗器械产品注册证 ，2025年2月获得 印度尼西亚C类医疗器械产品注册证 。 # 关于SkuHeal ™ 人工骨修复材料 SkuHeal ™ 人工骨修复材料是 奥精医疗 基于其具有完全自主知识产权的 体外仿生矿化技术研发和生产的一 种仿生矿化胶原人工骨修复材料 。该产品在组成成分和微观结构上均对人体天然骨组织高度仿生，能够在植 入体内后引导骨再生，并被新生骨组织爬行替代。 主要用于 神经外科相关的无植骨禁忌的骨缺损修复 ，包括骨折、骨不连、骨缺损等。具有良好的骨组织再生 修复能 ...

Market Overview - The A-share market is experiencing slight fluctuations, with the Shanghai Composite Index closing at 3387.40, down 0.04%, and the Shenzhen Component Index at 10151.43, down 0.12% [2][7] - The overall market capitalization of the Shanghai Composite Index is 6526.16 billion, with a price-to-earnings (PE) ratio of 12.03 and a price-to-book (PB) ratio of 1.25 [3] Industry Dynamics - The biomanufacturing sector is entering a critical phase, with a focus on overcoming the "pilot transformation" bottleneck to scale up the industry, aiming to cultivate over 20 pilot platforms by 2027 [26] - The storage chip market is witnessing price increases, with DDR4 prices rising by 17.50% week-on-week, and NAND products also showing price growth [29][30] - LG Energy Solution has secured an 8GWh order for cylindrical batteries from Chery Automobile, marking a significant contract in the electric vehicle battery supply chain [31] - The humanoid robot innovation center has established a subsidiary in Shenzhen, indicating growth in the robotics sector [33] - Meta and Oakley are launching smart glasses designed for sports, highlighting advancements in AI and wearable technology [35] Company Tracking - Wen's Foodstuffs (300498.SZ) reports continuous improvement in core production metrics for chicken and pig farming, with costs stabilizing [37] - Zhejiang Meida (002677.SZ) has announced an investment in smart driving technology, indicating a strategic shift towards emerging technologies [39] - Midea Group (000333.SZ) plans to repurchase shares worth between 50 to 100 billion, with a maximum repurchase price of 100 yuan per share [41] - Xinhua Medical (600587.SH) has received approval for a new medical device, enhancing its product portfolio in the healthcare sector [42] - Zai Jian Pharmaceutical (688266.SH) has received approval for clinical trials of its drugs for small cell lung cancer, marking a significant step in its oncology pipeline [44] - Ao Jing Medical (688613.SH) has obtained approval for its artificial bone repair material in Vietnam, expanding its market reach [47] - Bozhong Precision (688097.SH) is acquiring a 70% stake in Shanghai Wodian, enhancing its capabilities in industrial automation solutions [49]

Core Viewpoint - The company has issued a correction to its 2024 annual report, specifically regarding the sales dependency on major customers, indicating that two of the top five customers were new in 2024, which was not previously disclosed [1][2]. Group 1: Business Performance and Strategy - In 2024, the company accelerated its market expansion, developing over 900 new hospitals, with 800 of these due to the nationwide implementation of centralized procurement for orthopedic artificial bones, resulting in a 90% increase in terminal hospitals compared to the previous year [4][5]. - The company completed the acquisition of HumanTech Dental in April 2024, entering the dental implant market and establishing a diversified distribution system, which has shown rapid growth and is expected to become a new revenue driver [5]. - The company has made significant progress in international market expansion, obtaining medical device registrations in multiple Southeast Asian and Latin American countries, which is expected to enhance its global market presence [5]. Group 2: Operational Efficiency and Cost Management - The company has optimized its production operations, establishing a new production line capable of producing 2 million boxes of mineralized collagen artificial bone repair materials annually, which supports the increased clinical demand following centralized procurement [7][8]. - In 2025, the company plans to implement cost-reduction measures, enhance internal control management, and improve operational quality by optimizing production efficiency and managing inventory effectively [8][9]. Group 3: Innovation and R&D - The company is committed to long-term R&D investments, achieving significant breakthroughs in 2024, including the registration of new medical devices and the establishment of a postdoctoral research station to foster innovation and talent development [10]. - In 2025, the company aims to expand its R&D team and enhance collaboration mechanisms to improve product competitiveness and market share [10]. Group 4: Governance and Investor Relations - The company is focused on strengthening its governance structure and decision-making processes to enhance operational efficiency and accountability [11]. - The company emphasizes the importance of investor communication and aims to improve the quality of information disclosure while ensuring stable and continuous profit distribution policies [12][13].

Company Overview - Aojing Medical Technology Co., Ltd. focuses on the research, development, production, and sales of high-end biomedical materials and related medical devices, recognized as a national high-tech enterprise [1] - The company has consistently aimed to meet clinical needs through continuous innovation in products and technology, primarily researching and developing mineralized collagen artificial bone repair materials [1] Financial Performance - As of the first quarter of 2025, Aojing Medical reported revenue of 42.46 million yuan, a year-on-year decrease of 10.35% [1] - The net profit for the same period was 1.04 million yuan, reflecting a significant year-on-year decline of 84.99% [1] - The gross profit margin stood at 60.71% [1] Market Position - Aojing Medical's latest closing price was 16.15 yuan, with a market capitalization of 2.213 billion yuan and a price-to-book ratio of 1.57 [1] - The company is among eight institutions holding shares, with a total of 35.38 million shares valued at 561 million yuan [1] Industry Comparison - Aojing Medical's price-to-earnings (P/E) ratio (TTM) is -119.23, significantly lower than the industry average of 49.02 [2] - The industry median P/E ratio is 36.25, indicating that Aojing Medical is underperforming compared to its peers [2]

Group 1 - The U.S. "reciprocal tariffs" are putting significant pressure on the global economy and trade system, particularly affecting industries like semiconductors, automobiles, and pharmaceuticals [1] - Aojing Medical (688613.SH) stated that its overseas business is primarily focused on emerging markets in Southeast Asia, and the U.S. tariff policy will not impact its operations [1] - The company emphasizes its long-term global strategy, aiming to enhance product competitiveness through continuous technological innovation and to expand into high-growth emerging markets [1] Group 2 - The bone repair materials industry is experiencing a trend of domestic substitution, with artificial bone materials gradually replacing natural bone due to their advantages [2] - Aojing Medical's mineralized collagen artificial bone repair materials have achieved international advanced levels in key indicators, addressing limitations of natural bone materials [2] - The market share of artificial bone has rapidly increased from less than 30% in 2018 to a dominant position, indicating a clear trend towards accelerated substitution [2] Group 3 - The domestic bone repair materials industry has seen rapid development, with domestic brands catching up to or surpassing imported brands in technology [3] - National centralized procurement policies are driving domestic substitution, further squeezing the market space for imported products [3] - Aojing Medical's mineralized collagen artificial bone repair materials have become a benchmark for high-end orthopedic products in China, with significant growth in hospital adoption following successful procurement [3] Group 4 - Aojing Medical's product line includes various artificial bone repair materials, which are expected to enhance market share due to their inclusion in national procurement [4] - The company is diversifying its product offerings to mitigate the impact of price reductions from centralized procurement [4] - Aojing Medical is expanding into the dental implant market through the acquisition of HumanTech Dental, which is expected to create a second growth curve for the company [5] Group 5 - The company is focusing on emerging markets in Southeast Asia, having obtained regulatory approvals in Malaysia, Indonesia, and Vietnam, which are expected to drive growth [5][6] - The Southeast Asian orthopedic repair materials market is projected to grow at a compound annual growth rate of 21.4% from 2023 to 2028, significantly outpacing the global average [5] - Aojing Medical's early entry into the Southeast Asian market provides a competitive advantage amid the U.S.-China trade tensions [5] Group 6 - Aojing Medical's supply chain strategy emphasizes resilience and efficiency, aiming to combine low costs with rapid response capabilities [6] - The core materials for the company's artificial bone products are I-type collagen and hydroxyapatite, with plans for self-sufficiency in raw materials to reduce production costs [6] - A new production line set to launch in November 2024 will significantly increase the company's annual production capacity, supporting both domestic and international demand [6] Group 7 - Aojing Medical is leveraging technological innovation and a diversified product strategy to build a sustainable growth model in a competitive environment [7] - The company's strategic planning and rapid progress position it well to capitalize on growth opportunities in the bone repair materials market [7]

合作伙伴征集：2025全球手术机器人大会 奥精医疗 于2024年12月向越南卫生部递交了 BonGold™人工骨修复材料 的注册申报资料，并于2025年3月 13日正式获得注册证（注册证编号：2500502ĐKLH/BYT-HTTB），证件有效期为永久。该产品被归类为 D 类（高风险医疗器械） ，这表明其在安全性、有效性和质量控制方面达到了较高标准。 此次获批不仅是奥精医疗在东南亚市场的重要突破，也为其产品在海外市场的进一步推广奠定了基础。公司表 示，将积极推进BonGold™人工骨修复材料在越南的市场推广和销售工作，同时继续拓展其他海外市场，提升 产品的国际影响力。 # 产品介绍 BonGold™人工骨修复材料 是奥精医疗基于其具有完全自主知识产权的体外仿生矿化技术研发和生产的一种 仿生矿化胶原人工骨修复材料 。该产品在组成成分和微观结构上均对人体天然骨组织高度仿生，能够在植入 体内后引导骨再生，并被新生骨组织爬行替代，具有良好的骨组织再生修复能力。 报名：首届全球眼科大会 | 暂定议程名额有限 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 2025年3月19日， 奥精医疗科 ...

行业月度点评 医疗器械 证券研究报告 DeepSeek 加速 AI 医疗落地，建议关注相关企业 投资机遇 | 2025 年 03 月 10 日 | | | --- | --- | | 评级 | 领先大市 | | 评级变动： | 维持 | 行业涨跌幅比较 龙靖宁 分析师 执业证书编号:S0530523120001 longjingning@hnchasing.com | 重点股票 | 2023A | | 2024E | | 2025E | | 评级 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | EPS（元） PE（倍） EPS（元） PE（倍）EPS（元） PE（倍） | | | | | | 迈瑞医疗 | 9.55 | 25.56 | 11.4 | 21.41 | 13.27 | 18.39 | 买入 | | 维力医疗 | 0.66 | 17.83 | 0.82 | 14.35 | 0.99 | 11.89 | 增持 | | 新产业 | 2.10 | 28.79 | 2.30 | 26.29 | 2.66 | 22.73 | 增持 | | ...